Dr. Gaetano Scuderi is a Stanford-trained spine surgeon and early pioneer of orthobiologics who has spent decades working at the intersection of orthopedic surgery and molecular medicine. His work is rooted in a contrarian belief: degenerative disease should be treated by restoring biology, not replacing anatomy. That philosophy led him to study alpha-2-macroglobulin (A2M), a naturally occurring protease inhibitor capable of slowing cartilage degradation at its source, and to invent APIC (Autologous Protease Inhibitor Concentrate), a device-based therapy that has been used in more than 10,000 patients, including professional athletes.

In 2006, Dr. Scuderi founded Cytonics to pursue a more ambitious goal: engineering a recombinant, scalable biologic version of A2M suitable for global clinical development, giving rise to CYT-108. A 5th-degree black belt in Brazilian Jiu-Jitsu, he brings the same discipline, patience, and strategic thinking to biotech, where success is less about brute force and more about long-term positioning. He often compares drug development to a high-stakes chess match, where winning depends on anticipating moves ahead and executing with precision.